组织胞浆菌抗原持续与清除速率因免疫状态而异
单中心回顾性研究纳入2007至2021年83例经抗原检测阳性并治疗的组织胞浆菌病患者,比较不同免疫状态下的抗原清除速率与转阴时间。结果显示移植、生物制剂及其他免疫抑制患者抗原尿清除显著慢于免疫正常者和HIV感染者,抗原持续与免疫状态相关。
要点
- 移植、生物制剂及其他免疫抑制患者抗原尿清除速率显著低于HIV感染者和免疫正常者。
- 合并死亡竞争风险时,移植患者中位抗原转阴时间最长(20.3个月),免疫正常者最短(6.8个月)。
- 治疗1年时免疫抑制患者抗原阳性率显著高于免疫正常者(55% vs 19%,p=0.02)。
核心结论
- 慢性非HIV免疫抑制患者抗原尿持续且清除慢于免疫正常者及免疫重建的HIV感染者。
- 抗原持续与免疫状态相关,其在非HIV免疫抑制人群中的临床意义有待评估。
研究设计与样本
- 单中心回顾性研究,纳入2007至2021年经抗原检测阳性并接受治疗的成人组织胞浆菌病患者83例。
- 采用线性混合效应模型估计抗原清除平均速率,竞争风险分析计算抗原转阴时间。
主要发现
- 移植组、生物制剂组和其他免疫抑制组抗原尿清除速率分别为-0.07、-0.07、-0.05,显著慢于HIV感染组(-0.21)和免疫正常组(-0.16)。
- 合并死亡竞争风险时中位抗原转阴时间:移植20.3个月(95%CI 11.6–69.3),生物制剂14.6个月(9.0–42.6),其他免疫抑制13.2个月(2.0–82.5),HIV感染12.9个月(1.9–19.2),免疫正常6.8个月(2.8–13.0)。
- 治疗1年时免疫抑制患者抗原阳性率高于免疫正常者(22/40,55% vs 3/16,19%;p=0.02)。
- 免疫抑制组中仅移植、生物制剂和其他免疫抑制患者在2年时仍有抗原阳性。
临床怎么用
- 对非HIV免疫抑制的组织胞浆菌病患者,应预期抗原尿清除较慢、治疗疗程可能延长。
- 移植、生物制剂及其他免疫抑制患者需更长时间监测抗原直至转阴,尤其治疗1年后仍阳性者。
局限性
- 单中心回顾性设计,样本量有限(83例),各组人数较少。
- 既往抗原趋势研究多在HIV抗逆转录病毒治疗前时代,对现代队列外推性有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Previous studies examining Histoplasma antigen trends are largely in people living with HIV (PLWH) before the antiretroviral therapy era, with limited generalizability to modern cohorts of histoplasmosis. METHODS: We conducted a single-center, retrospective study of adult patients diagnosed with histoplasmosis by positive antigen testing and undergoing treatment between 2007 to 2021. Mean rates of antigen clearance were estimated using a linear mixed effects model. Time to H. capsulatum antigen negativity was calculated using competing risk analysis. Per-patient, mean antigen levels were compared at time of diagnosis and subsequent 6mo intervals. RESULTS: 83 patients met inclusion criteria: 25 transplant, 21 immunocompetent, 16 biologic therapy, 11 PLWH, and 10 with other immunocompromise (OI). The transplant (-0.07), biologic (-0.07), and OI groups (-0.05) cleared antigenuria significantly slower than PLWH (-0.21) and the immunocompetent group (-0.16). Median time to antigen negativity in the presence of competing risk of death was transplant: 20.3 months (95% CI: 11.6, 69.3), biologic: 14.6 months (9.0, 42.6), OI: 13.2 months (2.0, 82.5), PLWH: 12.9 months (1.9, 19.2), and immunocompetent: 6.8 months (2.8, 13.0). At one year, antigen positivity was more common in immunocompromised than immunocompetent patients (22/40, 55% vs. 3/16, 19%; p = 0.02) and among the immunocompromised groups only transplant, biologic, and OI patients had positivity at two years. CONCLUSIONS: Patients with chronic non-HIV immunosuppression demonstrated persistent antigenuria and cleared antigen more slowly compared to immunocompetent patients and immune reconstituted PLWH. Given the association of antigen persistence with immune status, its clinical significance in non-HIV immunocompromised populations requires evaluation.
引用
- Fallon SM, Zuniga-Moya JC, Rauseo A, et al. Histoplasma Capsulatum Antigen Persistence and Rate of Decay During Treatment of Histoplasmosis Varies by Immune Status. Clin Infect Dis. 2026. PMID: 42700964. doi:10.1093/cid/ciag533
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。